SAN DIEGO, Oct. 5, 2015 /PRNewswire/ -- Sequenom, Inc.
(NASDAQ: SQNM), a life sciences company committed to enabling
healthier lives through the development of innovative products and
services, today announced that it has entered into a clinical
collaboration with Seoul National
University Hospital (SNUH). SNUH and Sequenom will
collaborate to profile circulating cell-free tumor DNA in blood in
a series of research studies targeting several hundred patients
across a wide variety of cancer types.
"We are looking forward to collaborating with Sequenom on the
clinical evaluation of their new liquid biopsy assay," said
Yung-Jue Bang, MD, PhD, Professor in
the Department of Internal Medicine at Seoul National University Hospital. "We believe that
liquid biopsy has the potential to significantly improve clinical
care in a variety of cancer management settings."
"This is Sequenom's first oncology collaboration with a leading
medical center in Asia," said
Daniel Grosu, M.D., Chief Medical
Officer at Sequenom. "We are excited to work with SNUH on
evaluating our liquid biopsy assay in a substantial number of
clinical samples. Among other objectives, this study will enable us
to comprehensively analyze the genomic alterations concordance
between tissue and blood in different cancers."
Sequenom is currently developing a Research Use Only (RUO) assay
with an initial focus on the detection and molecular profiling of
late stage non-hematologic malignancies in settings where tissue
biopsies are not available or are too risky to obtain. The
assay will cover a breadth of cancer types by analyzing over 100
cancer-related genes that are included in professional society
guidelines, linked to targeted therapies currently in clinical
trials, or part of well-documented cancer pathways. This clinical
research study will aim to enroll several hundred patients across
10 different cancer types.
About Seoul National University
Hospital
Through the historical tradition of
Jejungwon and Daehan Hospital, Seoul National
University Hospital (SNUH), as the representative medical
center of Korea, has been heralded as a national development engine
raising the nation's healthcare system to world-class standards in
the medical sciences, as well as medical education, research, and
patient care. Currently, SNUH consists of different branches that
have grown over the years as an extension of the main branch
located in Daehak-ro: SNU Bundang Hospital, SMG-SNU Boramae Medical
Center, SNUH Healthcare System Gangnam Center, SNU Children's Hospital, and SNU Cancer
Hospital.
About Sequenom
Sequenom, Inc.
(NASDAQ: SQNM) is committed to enabling healthier lives through the
development of innovative products and services. The Company serves
patients and physicians by providing early patient management
information. To learn how Sequenom is interpreting the genome to
improve your life, visit www.sequenom.com.
SEQUENOM®, Sequenom Laboratories™,
HerediT® CF, HerediT® UNIVERSAL,
VisibiliT™, MaterniT21® PLUS,
MaterniT™ GENOME, and NextView™, are
trademarks of Sequenom, Inc. All other trademarks and service marks
are the property of their respective owners.
Forward-Looking
Statements contained in
this press release regarding matters that are not historical facts
are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 including statements
regarding the development of innovative products and services, the
belief that liquid biopsy has the potential to significantly
improve clinical care in a variety of cancer management settings,
the ability of the study to comprehensively analyze the genomic
alterations concordance between tissue and blood in different
cancers, the ability of the assay to cover a breadth of cancer
types by analyzing over 100 cancer-related genes and the ability to
enroll several hundred patients across 10 different cancer types
for the study. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements.
Risks are described more fully in the Company's filings with the
Securities and Exchange Commission, including without limitation
the Company's most recent Quarterly Report on Form 10-Q and other
documents subsequently filed with or furnished to the Securities
and Exchange Commission. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. The Company undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were
made.
![SEQUENOM logo. SEQUENOM logo.](http://photos.prnewswire.com/prnvar/20040415/SQNMLOGO)
Logo - http://photos.prnewswire.com/prnh/20040415/SQNMLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sequenom-enters-clinical-collaboration-with-seoul-national-university-hospital-300153838.html
SOURCE Sequenom, Inc.